+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Meningococcal Vaccine Market by Serogroup, Vaccine Type and End User: Global Opportunity Analysis and Industry Forecast, 2018-2026

  • ID: 5118794
  • Report
  • April 2020
  • Region: Global
  • 197 pages
  • Allied Analytics LLP

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bio-Manguinhos
  • Bio-Med Pvt. Limited
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi S.A.
  • MORE
The global meningococcal vaccine market was valued at $1,935.5 million in 2018, and is projected to reach $4,192.5 million by 2026, registering a CAGR of 9.5% from 2019 to 2026. Invasive meningococcal disease (IMD) is a bacterial infection caused by a gram-negative coccus, Neisseria meningitidis, which includes spectrum of infections including meningitis, bacteremia (meningococcemia), and bacteremia pneumonia. Although meningococcal disease is rare but is associated with high fatality of up to 50% if left untreated and often results in serious complications thereafter. Meningococcal meningitis results in infection of the lining of the brain and spinal cord and also has a potential to cause large epidemics as well as endemics. The disease is generally transmitted through direct contact with droplets of respiratory or throat secretions from patients or asymptomatic carriers. Various serotypes of N. meningitidis are included in 12 serogroups of which only 5 serogroups including A, B, C, W, and Y are responsible for the majority of disease worldwide. However, circulation of these serogroups is highly unpredictable and varies over time across age groups and geographies. Vaccines for each of these serogroups are available in the market.

It is estimated that the meningococcal vaccine market is expected to experience significant market growth during the forecast period as there has been an increase in adoption in several countries across the globe in their national immunization programs. In addition, surge in meningococcal outbreaks in several countries has led to upsurge in demand for meningococcal vaccines, which further facilitate the growth of the market. However, stringent government regulations for the approval of new vaccines and recall of several products due to contamination are expected to impede market growth. In contrast, high population base in emerging markets and global increase in healthcare spending provides significant growth opportunities for the meningococcal vaccine market.

The global meningococcal vaccine market is segmented on the basis of serogroup, vaccine type, end user, and region. The serogroups covered in the study include MenACWY, MenB/BC, MenC, MenAC, and MenA. Depending on vaccine type, the market is classified into conjugate, polysaccharide, and subcapsular. According to end user, the market is segmented into pediatric, adults, and travelers. By region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, the Netherlands, Spain, and rest of Europe), Asia-Pacific (China, Australia, and rest of Asia-Pacific), and LAMEA (Latin America, the Middle East, and Africa).

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS

By Vaccine Serotype
  • MenACWY
  • MenB & MenBC
  • MenC
  • MenA
  • MenAC
By Vaccine Type
  • Conjugate
  • Polysaccharide
  • Subcapsular
By End User
  • Pediatric
  • Adult
  • Travelers
By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • the Netherlands
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Latin America
  • Middle-East
  • Africa
LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Bio-Manguinhos
  • Bio-Med Pvt. Limited
  • Chongqing Zhifei Biological Products Co., Ltd.
  • GlaxoSmithKline Plc
  • Hualan Biological Engineering Inc.
  • Incepta Pharmaceuticals Ltd.
  • Pfizer INC
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd
  • Walvax Biotechnology Co., Ltd.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bio-Manguinhos
  • Bio-Med Pvt. Limited
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi S.A.
  • MORE
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled in the Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools and Models

Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.1.1. Cxo Perspective

Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Buyers
3.3.2. Bargaining Power of Suppliers
3.3.3. Thereat of New Entrants
3.3.4. Threat of Substitutes
3.3.5. Intensity of Competitive Rivalry
3.3.6. Market Share Analysis, 2018
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Increase in Outbreaks of Meningococcal Disease
3.4.1.2. Surge in Immunization Programs Across the Globe
3.4.1.3. Increase in Research and Development for Vaccine Technology
3.4.2. Restraint
3.4.2.1. Longer Timelines Required for Vaccine Production
3.4.2.2. High Costs Associated With the Development of Vaccines
3.4.3. Opportunities
3.4.3.1. Growth Opportunities in the Emerging Markets
3.4.3.2. Increase in Healthcare Spending
3.4.3.3. Increase in Research and Development for Meningococcal Vaccines
3.4.4. Impact Analysis

Chapter 4: Meningococcal Vaccine Market, by Vaccine Serotype
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Menacyw Vaccine
4.2.1. Key Market Trends, Growth Factors, and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Analysis, by Country
4.3. Menb/Bc Vaccine
4.3.1. Key Market Trends, Growth Factors, and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Analysis, by Country
4.4. Menc Vaccine
4.4.1. Key Market Trends, Growth Factors, and Opportunities
4.4.2. Market Size and Forecast, by Region
4.4.3. Market Analysis, by Country
4.5. Mena Vaccine
4.5.1. Key Market Trends, Growth Factors, and Opportunities
4.5.2. Market Size and Forecast, by Region
4.5.3. Market Analysis, by Country
4.6. Menac Vaccine
4.6.1. Key Market Trends, Growth Factors, and Opportunities
4.6.2. Market Size and Forecast, by Region
4.6.3. Market Analysis, by Country

Chapter 5: Meningococcal Vaccine Market, by Vaccine Type
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Conjugate Meningococcal Vaccines
5.2.1. Market Size and Forecast, by Region
5.2.2. Market Analysis, by Country
5.3. Polysaccharide Vaccine
5.3.1. Market Size and Forecast, by Region
5.3.2. Market Analysis, by Country
5.4. Subcapsular Vaccines
5.4.1. Market Size and Forecast, by Region
5.4.2. Market Analysis, by Country

Chapter 6: Meningococcal Vaccine Market, by End-user
6.1. Overview
6.1.1. Market Size and Forecast
6.2. Pediatrics
6.2.1. Market Size and Forecast
6.2.2. Market Analysis, by Country
6.3. Adults
6.3.1. Market Size and Forecast
6.3.2. Market Analysis, by Country
6.4. Traveler
6.4.1. Market Size and Forecast
6.4.2. Market Analysis, by Country

Chapter 7: Meningococcal Vaccine Market by Region
7.1. Overview
7.1.1. Market Size and Forecast
7.2. North America
7.2.1. Key Market Trends, Growth Factors, and Opportunities
7.2.2. Market Size and Forecast, by Country
7.2.2.1. U. S.
7.2.2.1.1. U. S. Meningococcal Vaccine Market, by Vaccine Serotype
7.2.2.1.2. U. S. Meningococcal Vaccine Market, by Vaccine Type
7.2.2.1.3. U. S. Meningococcal Vaccine Market, by End-user
7.2.2.2. Canada
7.2.2.2.1. Canada Meningococcal Vaccine Market, by Vaccine Serotype
7.2.2.2.2. Canada Meningococcal Vaccine Market, by Vaccine Type
7.2.2.2.3. Canada Meningococcal Vaccine Market, by End-user
7.2.2.3. Mexico
7.2.2.3.1. Mexico Meningococcal Vaccine Market, by Vaccine Serotype
7.2.2.3.2. Mexico Meningococcal Vaccine Market, by Vaccine Type
7.2.2.3.3. Mexico Meningococcal Vaccine Market, by End-user
7.2.3. North America Meningococcal Vaccine Market, by Vaccine Serotype
7.2.4. North America Meningococcal Vaccine Market, by Vaccine Type
7.2.5. North America Meningococcal Vaccine Market, by End-user
7.3. Europe
7.3.1. Key Market Trends, Growth Factors, and Opportunities
7.3.2. Market Size and Forecast, by Country
7.3.2.1. Germany
7.3.2.1.1. Germany Meningococcal Vaccines Market, by Serotype
7.3.2.1.2. Germany Meningococcal Vaccines Market, by Vaccine Type
7.3.2.1.3. Germany Meningococcal Vaccines Market, by End-user
7.3.2.2. France
7.3.2.2.1. France Meningococcal Vaccines Market, by Serotype
7.3.2.2.2. France Meningococcal Vaccines Market, by Vaccine Type
7.3.2.2.3. France Meningococcal Vaccines Market, by End-user
7.3.2.3. UK
7.3.2.3.1. UK Meningococcal Vaccines Market, by Serotype
7.3.2.3.2. UK Meningococcal Vaccines Market, by Vaccine Type
7.3.2.3.3. UK Meningococcal Vaccines Market, by End-user
7.3.2.4. The Netherlands
7.3.2.4.1. The Netherlands Meningococcal Vaccines Market, by Serotype
7.3.2.4.2. The Netherlands Meningococcal Vaccines Market, by Vaccine Type
7.3.2.4.3. The Netherlands Meningococcal Vaccines Market, by End-user
7.3.2.5. Spain
7.3.2.5.1. Spain Meningococcal Vaccines Market, by Serotype
7.3.2.5.2. Spain Meningococcal Vaccines Market, by Vaccine Type
7.3.2.5.3. Spain Meningococcal Vaccines Market, by End-user
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe Meningococcal Vaccines Market, by Serotype
7.3.2.6.2. Rest of Europe Meningococcal Vaccines Market, by Vaccine Type
7.3.2.6.3. Rest of Europe Meningococcal Vaccines Market, by End-user
7.3.3. Europe Meningococcal Vaccines Market, by Serotype
7.3.4. Europe Meningococcal Vaccines Market, by Vaccine Type
7.3.5. Europe Meningococcal Vaccines Market, by End-user
7.4. Asia-Pacific
7.4.1. Key Market Trends, Growth Factors, and Opportunities
7.4.2. Market Size and Forecast, by Country
7.4.2.1. China
7.4.2.1.1. China Meningococcal Vaccine Market, by Vaccine Serotype
7.4.2.1.2. China Meningococcal Vaccine Market, by Vaccine Type
7.4.2.1.3. China Meningococcal Vaccine Market, by End-user
7.4.2.2. Australia
7.4.2.2.1. Australia Meningococcal Vaccine Market, by Vaccine Serotype
7.4.2.2.2. Australia Meningococcal Vaccine Market, by Vaccine Type
7.4.2.2.3. Australia Meningococcal Vaccine Market, by End-user
7.4.2.3. Rest of Asia-Pacific
7.4.2.3.1. Rest of Asia-Pacific Meningococcal Vaccine Market, by Vaccine Serotype
7.4.2.3.2. Rest of Asia-Pacific Meningococcal Vaccine Market, by Vaccine Type
7.4.2.3.3. Rest of Asia-Pacific Meningococcal Vaccine Market, by End-user
7.4.3. Asia-Pacific Meningococcal Vaccine Market, by Vaccine Serotype
7.4.4. Asia-Pacific Meningococcal Vaccine Market, by Vaccine Type
7.4.5. Asia-Pacific Meningococcal Vaccine Market, by End-user
7.5. LAMEA
7.5.1. Key Market Trends, Growth Factors, and Opportunities
7.5.2. Market Size and Forecast, by Country
7.5.2.1. Latin America
7.5.2.1.1. Latin America Meningococcal Vaccines Market, by Serotype
7.5.2.1.2. Latin America Meningococcal Vaccines Market, by Vaccine Type
7.5.2.1.3. Latin America Meningococcal Vaccines Market, by End-user
7.5.2.2. Middle East
7.5.2.2.1. Middle East Meningococcal Vaccines Market, by Serotype
7.5.2.2.2. Middle East Meningococcal Vaccines Market, by Vaccine Type
7.5.2.2.3. Middle East Meningococcal Vaccines Market, by End-user
7.5.2.3. Africa
7.5.2.3.1. Africa Meningococcal Vaccines Market, by Serotype
7.5.2.3.2. Africa Meningococcal Vaccines Market, by Vaccine Type
7.5.2.3.3. Africa Meningococcal Vaccines Market, by End-user
7.5.3. LAMEA Meningococcal Vaccines Market, by Serotype
7.5.4. LAMEA Meningococcal Vaccines Market, by Vaccine Type
7.5.5. LAMEA Meningococcal Vaccines Market, by End-user

Chapter 8: Company Profiles
8.1. Bio-Manguinhos
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.2. Bio-Med Pvt. Limited
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.3. Chongqing Zhifei Biological Products Co. Ltd.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.4. GlaxoSmithKline plc
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.4.1. Key Strategic Moves and Developments
8.5. Hualan Biological Engineering Inc.
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.6. Incepta Pharmaceuticals Ltd.
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.7. Pfizer Inc.
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.8. Sanofi S. A.
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.9. Serum Institute of India Pvt. Ltd
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.10. Walvax Biotechnology Co. Ltd.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bio-Manguinhos
  • Bio-Med Pvt. Limited
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi S.A.
  • MORE
According to the report titled, 'Meningococcal Vaccine Market by Vaccine Serotype, Vaccine Type, and End User: Opportunity Analysis and Industry Forecast, 2018-2026', the global meningococcal vaccines market size was valued at $1,935.54 million in 2018, and is projected to reach $4.19 billion by 2026, registering a CAGR of 9.5% from 2019 to 2026.

Bacterial infections can be prevented by immunization and therefore, immunization is crucial. Neisseria meningitidis, is a virus that causes diseases such as meningitis, bacteremia (meningococcemia), and bacteremia pneumonia. However, these infectious diseases can be prevented by the use of meningococcal vaccines. Meningococcal vaccines are administered to both children and adults in a pattern of two doses to ensure complete immunization. There are three different types of meningococcal vaccines such as conjugate, polysaccharide, and subcapsular meningococcal vaccines.

Rise in immunization programs worldwide is the major factor that boost the growth of the meningococcal vaccine market. In addition, factors such as surge in awareness related to the use of meningococcal vaccines and increase in adoption of vaccination across the globe fuel the growth of the meningococcal vaccine market. However, high monetary inputs associated with manufacture of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the meningococcal vaccine market growth during the forecast period.

The global meningococcal vaccine market is segmented on the basis of serotype, vaccine types, and end user. On the basis of serotype, the market is classified into Men ACYW, Men B/BC, Men C/CY, Men AC, and Men A. By vaccine type, it is divided into conjugate, polysaccharide, and subcapsular. On the basis of end user, it is segmented into pediatric, adult, and traveler. Based on region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, the UK, Spain, France, the Netherland, and rest of Europe), Asia-Pacific(China, Australia, and rest of Asia-Pacific), and LAMEA (Latin America.

Based on Serotypes, the meningococcal vaccine segment constituted for the major share of the meningococcal vaccine market and is expected to experience rapid growth during the forecast period as these vaccines exhibit increase in adoption in several countries and inclusion of vaccines in their national immunization programs. Moreover, Meningococcal meningitis outbreaks in several countries has led to upsurge in demand for meningococcal vaccines, which further swelled up the growth of the market is another reason that boosts the growth of the meningococcal vaccine market.

On the basis of region, North America acquired a major share owing to easy availability of meningococcal vaccines, presence of skilled healthcare experts, and presence of major key players that offer meningococcal vaccines. The Asia-Pacific region is expected to grow at the fastest rate during the forecast period due to surge in awareness related to importance of immunization, presence of large population, and rise in disposable income.

The developing economies offer lucrative opportunities for meningococcal vaccine providers to expand their business. The constantly evolving healthcare industry drives the growth of the market in the developing economies such as Africa, China, and others ca, the Middle East, and Africa).

Key Findings Of The Study

As per the serotype, the MenACWY vaccine segment is accounted for the highest market share of 54% in 2018 and is anticipated to grow at a CAGR of 11.7% during the forecast period.
On the basis of the vaccine type, the conjugate vaccine segment accounted for the largest market share and is anticipated to be the fastest growing segment at a CAGR of 10.2%.
By end user, the hospitals & clinics segment is expected to grow at the highest CAGR of 11.6% from 2019 to 2026, in terms of value.
Region wise, North America was the major shareholder and accounted for 49.84% of the meningococcal vaccine market share in 2018.

Comprehensive competitive analysis and profiles of major market players such as Bio-Manguinhos, Bio-Med Pvt. Limited, Chongqing Zhifei Biological Products Co., Ltd., GlaxoSmithKline Plc, Hualan Biological Engineering Inc., Incepta Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd, and Walvax Biotechnology Co., Ltd. are provided in this report.
Note: Product cover images may vary from those shown
  • Bio-Manguinhos
  • Bio-Med Pvt. Limited
  • Chongqing Zhifei Biological Products Co. Ltd.
  • GlaxoSmithKline Plc
  • Hualan Biological Engineering Inc. Inc.pta Pharmaceuticals Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd
  • Walvax Biotechnology Co. Lt
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll